Core Insights - Becton Dickinson and Co. (BDX) is a leading global medical technology company that develops, manufactures, and sells medical devices, instrument systems, and reagents, operating through three segments: BD Medical, BD Life Sciences, and BD Interventional [1] Financial Performance - On February 10, 2026, BDX executed a stock split with a ratio of 125 for 159, aimed at making shares more affordable [2][4] - BDX reported first-quarter 2026 adjusted earnings of $2.91 per share, exceeding the consensus estimate of $2.81, with sales reaching $5.25 billion, slightly above the expected $5.15 billion [2][4] Strategic Changes - BDX is undergoing significant changes, including the separation of its Biosciences and Diagnostic Solutions businesses and a combination with Waters Corporation [3] - The company has lowered its fiscal 2026 adjusted earnings guidance from a range of $14.75-$15.05 per share to $12.35-$12.65 per share, compared to the consensus of $14.72, indicating a transition year according to RBC Capital Markets [3] Stock Performance - BDX's stock is currently priced at $180.62, reflecting an increase of 5.21% or $8.94, with fluctuations between a low of $170.67 and a high of $181.98 during the trading day [3] - Over the past year, BDX has reached a high of $185.02 and a low of $127.59, with a market capitalization of approximately $51.44 billion and a trading volume of 4,441,319 shares on the NYSE [3]

Core Insights - BD reported earnings per share (EPS) of $2.91, exceeding estimates of $2.82, indicating strong financial performance in fiscal 2026 [2] - Revenue increased by 1.6% to $5.3 billion, surpassing the estimated $5.15 billion, with a foreign exchange-neutral revenue rise of 0.4% [2] - The merger with Waters Corporation aims to enhance shareholder value and is expected to contribute to gross margin expansion [3] Financial Performance - BD's price-to-earnings (P/E) ratio is approximately 35.87, indicating a premium investors are willing to pay for earnings [5] - The price-to-sales ratio stands at about 2.74, while the enterprise value to sales ratio is 3.58, reflecting the value placed on its sales [5] - The debt-to-equity ratio is approximately 0.76, suggesting a balanced approach to financing assets [5] Strategic Initiatives - The merger with Waters Corporation combines BD's Biosciences and Diagnostic Solutions business, focusing on innovation and productivity [3] - Tom Polen, BD's chairman and CEO, expressed confidence in the company's future prospects and affirmed revenue growth guidance for fiscal year 2026 [4]